Company: DMAC
Filing Date: 2025-08-01
Form Type: S-3
Source: 0001437749-25-024290
Chunk: 2

Company: DiaMedica Therapeutics Inc.
Filing Date: 2025-08-01
Form: S-3
Chunk 2
---
 COMPLETION, DATED August 1, 2025</div>

PRELIMINARY PROSPECTUS

<div align='center'>8,606,425 COMMON SHARES</div>

This prospectus relates to the resale, from time to time, of up to an aggregate of 8,606,425 common shares, no par value per share, of DiaMedica Therapeutics Inc. by the selling shareholders named in this prospectus, including their respective donees, pledgees, transferees, assignees or other successors-in-interest. The selling shareholders acquired these shares from us in a private placement transaction pursuant to Securities Purchase Agreements, dated as of July 21, 2025, (the “Securities Purchase Agreements”) pursuant to which we issued an aggregate of 8,606,425 common shares at a purchase price of $3.50 per share.

We are not selling any common shares under this prospectus and will not receive any proceeds from sales of the common shares offered by the selling shareholders, although we will incur expenses in connection with the offering. The registration of the resale of the common shares covered by this prospectus does not necessarily mean that any of the shares will be offered or sold by the selling shareholders. The timing and amount of any sales are within the sole discretion of the selling shareholders.

The common shares offered under this prospectus may be sold by the selling shareholders through public or private transactions, on or off The Nasdaq Capital Market, at prevailing market prices or at privately negotiated prices. For more information on the times and manner in which the selling shareholders may sell the common shares under this prospectus, please see the section entitled “Plan of Distribution,” beginning on page 33 of this prospectus.

Our common shares are listed on The Nasdaq Capital Market under the symbol “DMAC.” On July 30, 2025, the last reported sales price of our common shares as reported on The Nasdaq Capital Market was $4.45 per share.

Investing in our common shares involves a high degree of risk. See“Risk Factors”beginning on page 6 of this prospectus, as well as those risk factors described in the documents we incorporate by reference.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense.

<div align='center'>The date of this prospectus is , 2025.

TABLE OF CONTENT